戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 clized peptides, a resemblance heightened by heterologous prime-boost.
2 s in successive immunization campaigns or as heterologous prime-boost agents.
3 y of these constructs was evaluated using a "heterologous prime-boost" approach consisting of mucosal
4 rS-WU1) or rS-Beta alone, in combination, or heterologous prime-boost, are protected from challenge.
5    In sum, we demonstrate that a therapeutic heterologous prime-boost-boost (HPBB) vaccine can elicit
6 Completing the serial immunization steps for heterologous prime-boost-boost can be lengthy, leaving t
7                                              Heterologous prime-boost-boost immunization has been sho
8  activated mouse T cells in vivo using acute heterologous prime-boost-boost vaccinations(4), transfer
9  immunodeficiency virus (SIV)-gag-containing heterologous prime-boost-boost vaccine established memor
10  Ten Mamu-B*08(+) RMs were vaccinated with a heterologous prime/boost/boost regimen encoding Vif and
11                   These results suggest that heterologous prime-boost combinations have distinct immu
12  poxvirus NYVAC-HIV vectors in homologous or heterologous prime-boost combinations in mice.
13 sing vaccines against bovine TB are based on heterologous prime-boost combinations that include BCG,
14 e been widely used in various homologous and heterologous prime-boost combinations.
15                                       Use of heterologous prime-boost COVID-19 vaccine schedules coul
16                                              Heterologous prime-boosting has emerged as a powerful va
17                              Here, we used a heterologous prime-boost immunization approach using a c
18                                         Such heterologous prime-boost immunization approaches may pro
19                                         This heterologous prime-boost immunization induced elevated l
20                                   AdCh63-MVA heterologous prime-boost immunization induces strong and
21 binations of i.m. and intravaginal routes in heterologous prime-boost immunization regimens with unre
22                                              Heterologous prime-boost immunization strategies can evo
23                                              Heterologous prime-boost immunization strategies have th
24              We also describe homologous and heterologous prime-boost immunization strategies using n
25 vel vaccine were assessed in mice by using a heterologous prime-boost immunization strategy and compa
26                                              Heterologous prime-boost immunization with plasmid DNA a
27 re examined by using multiple homologous and heterologous prime/boost immunization regimens in order
28                                          The heterologous prime/boost immunization regimens that invo
29 ntrast, Mamu-A*01+ monkeys that had received heterologous prime/boost immunizations prior to challeng
30 ors, the possibility has arisen of employing heterologous prime/boost immunizations using diverse mem
31                Recent clinical trials of new heterologous prime-boost malaria vaccine regimens using
32                                              Heterologous prime-boost may provide a more effective va
33  a single immunization or in a homologous or heterologous prime-boost modality.
34 s shown that vaccination strategies based on heterologous prime-boost protocols using Mycobacterium b
35            ChAd63-MVA AMA1 administered in a heterologous prime-boost regime was shown to be safe and
36 used to vaccinate rhesus macaques with a new heterologous prime-boost regimen designed to optimize in
37                These vectors, when used in a heterologous prime-boost regimen in BALB/c mice, are cap
38                  In contrast, an accelerated heterologous prime-boost regimen involving administratio
39 hrocytic vaccine will likely be based upon a heterologous prime-boost regimen that induces both appro
40 on a new duck cell line either alone or in a heterologous prime-boost regimen with recombinant chimpa
41 ted its immunogenicity early in life using a heterologous prime-boost regimen.
42             In this study, we show that such heterologous prime boost regimens based on E1-deleted ad
43 rime AIDS virus-specific T-cell responses in heterologous prime boost regimens.
44                                        Thus, heterologous prime-boost regimens boost CD4(+) as well a
45 Moreover, anatomic separation strategies and heterologous prime-boost regimens generated codominant r
46                                              Heterologous prime-boost regimens have been shown to eli
47 his study supports the rationale for testing heterologous prime-boost regimens in humans.
48                                              Heterologous prime-boost regimens induce potent cellular
49 frequency, that both protein- and mRNA-based heterologous prime-boost regimens induced VRC01-class an
50                 The standard and accelerated heterologous prime-boost regimens were well-tolerated an
51 e vaccinated 30 macaques with homologous and heterologous prime-boost regimens with BNT162b2 and Ad26
52 to evaluate the safety and immunogenicity of heterologous prime-boost regimens, with a New York vacci
53 3-specific CTLs can, however, be expanded by heterologous prime-boost regimens.
54 serotype Ad vectors than with Ad5 vectors in heterologous prime-boost regimens.
55 nses when administered with rVSVN4CT1gag1 in heterologous prime-boost regimens.
56 f cytotoxic-T-lymphocyte responses have been heterologous prime/boost regimens employing a plasmid DN
57                                              Heterologous prime/boost regimens have the potential for
58                                              Heterologous "prime-boost" regimens that involve priming
59 t human randomised clinical trial to explore heterologous prime-boost regimes using aerosol and syste
60                                              Heterologous prime-boost strategies are of interest for
61 cination groups evaluating homologous versus heterologous prime-boost strategies with 2 different boo
62  future clinical trials testing vector-based heterologous prime-boost strategies.
63 nds in vaccination strategies, particularly "heterologous prime-boost" strategies against tumors, and
64 munogenicity of the vaccines, we developed a heterologous prime-boost strategy with each of the vacci
65 ed MV vaccines to be used early in life in a heterologous prime-boost strategy.
66 findings support further development of this heterologous prime-boost strategy.IMPORTANCE Immune resp
67 aepithelial neoplasia were vaccinated with a heterologous prime/boost strategy consisting of gene gun
68                                         In a heterologous prime-boost study, ChulaCov19 booster dose
69  the current live attenuated MV vaccine in a heterologous prime-boost to protect against measles earl
70                                              Heterologous prime boost vaccination minimizes contracti
71                         This study exploited heterologous prime boost vaccination to discover paramet
72                                              Heterologous prime-boost vaccination has been shown to b
73                                         Only heterologous prime-boost vaccination induced modest cros
74                          Here we show that a heterologous prime-boost vaccination regime of DNA eithe
75                                  CMB305 is a heterologous prime-boost vaccination regimen created to
76                   These results suggest that heterologous prime-boost vaccination regimens enhance im
77 ng the best combination of vector systems in heterologous prime-boost vaccination regimens.IMPORTANCE
78                                              Heterologous prime-boost vaccination results in increase
79 tance of selecting optimal priming agents in heterologous prime-boost vaccination settings.
80                 In this study, we employed a heterologous prime-boost vaccination strategy comprising
81 f the JCI, Ruhl et al. developed a promising heterologous prime-boost vaccination strategy for EBV-as
82 these data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT
83         This study reports the efficacy of a heterologous prime-boost vaccination using DNA and vacci
84                         We demonstrated that heterologous prime-boost vaccination with the nuclear an
85                   We explored the concept of heterologous prime/boost vaccination using 2 therapeutic
86                    Our study shows that such heterologous prime-boost vaccinations against EBV-associ
87 hese findings suggest that administration of heterologous prime-boost vaccinations targeting EBNA1 ma
88                                          The heterologous prime-boost vaccine regimen used recombinan
89     These data suggest potential benefits of heterologous prime-boost vaccine regimens for SARS-CoV-2
90                                              Heterologous prime-boost vaccine regimens induced partic
91                 Our results demonstrate that heterologous prime-boost vaccine regimens with alternati
92 rhesus monkeys and can be combined as potent heterologous prime-boost vaccine regimens.
93                    ChAd63-MVA is a promising heterologous prime-boost vaccine strategy that could be
94 at CD4(+) and CD8(+) T cell responses with a heterologous prime/boost vaccine approach could induce l
95                                              Heterologous prime/boost viral vectored vaccination has
96                    Neutralising titres after heterologous prime-boost were at least comparable or hig
97                                              Heterologous prime-boost with the viral vectors simian a
98                                              Heterologous prime/boost with Cy/GVAX and CRS-207 extend